New malaria drug for newborns offers hope in Uganda
The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early'.
Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care.
Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication.
That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (about two to five kilograms).
Swissmedic said the treatment, a sweet-tasting tablet that dissolves into a syrup when dropped into liquids like breast milk, was approved in coordination with the World Health Organization (WHO) under a fast-track authorisation process to help developing countries access much-needed treatment.
Africa's 1.5 billion people accounted for 95 per cent of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children.
In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than five and pregnant women, the WHO said.
Nigeria, Congo, and Uganda – in that order – are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water.
The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children.
Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity.
Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals.
How the medicine could change malaria treatment
The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants.
Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitising the people adhering to treatment.
Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said.
During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centres across Uganda. Many are often women with babies strapped to their backs.
Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said.
'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies.
The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria'.
In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said.
Jane Nabakooza, a pediatrician with Uganda's malaria control programme, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the United States shrank its foreign aid programme earlier this year.
Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programmes such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite.
Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under five years,' Nabakooza said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fashion Network
5 hours ago
- Fashion Network
'Curly is beautiful': Tunisian women embrace natural hair
In countries around the world, beauty standards have shifted radically in recent years, with a growing number of beauty salons and cosmetic brands in Tunisia promoting natural styles. Still, the battle is far from won, and many women in Tunisia still rush to get their hair straightened ahead of a wedding or a meeting, and some fear that if they do not wear their hair straight for a job interview, they might not get hired. Advocates for wearing one's natural hair believe that at the root of the stigma around curls lies a form of discrimination that they call "texturism". "The further you move away from what is considered Afro, kinky or curly, the more socially accepted you are," said Nawal Benali, a journalist and host of a podcast on racism in North Africa. "Because that's a marker of proper appearance and presentability." Benali said the standards had first been set in "the white, Western world", calling the obsession around straight hair an attempt to "erase our Indigenous and African features". Dhouha Mechergui, who co-founded Pineapple Studio, recalled having her hair straightened by her mother ahead of every religious holiday growing up. She said it took courage to make her own switch to natural, and that she had to work hard to convince women to embrace their curls and come to her salon. "Sometimes I play the role of psychiatrist, because I know making that decision is very difficult," she said. Aside from the drive for greater authenticity, health concerns have become a part of the debate, with one major study by the US National Institutes of Health linking chemical hair straightening products to a higher risk of uterine cancer. For generations, people around the world were told to straighten, braid, cut or otherwise conceal their curls, or else get sent home from school or work. A global drive buoyed by the Black Lives Matter movement gave rise to a major pandemic-era trend of beauty videos celebrating natural hair. The push did not go unnoticed: French lawmakers last year voted to ban discrimination based on hair texture, while several US states have passed similar legislation. Tunisia has no such initiative, so women entrepreneurs are leading the change. In 2021, Sirine Cherif cofounded Kamaana -- or "as I am" -- Tunisia's first homegrown haircare brand dedicated to curly locks. "When we started, we were the only specialised brand on the market," she said. "A few months later, there was a domino effect: bigger brands launched their own curly-hair lines." And today, Tunisian companies such as Zynia and Lilas Cosmetics have joined the growing industry. For Cherif, the boom is both a lucrative business opportunity and a marker of profound social change. "We are proud to have encouraged people to be themselves, to resist this societal pressure and embrace their natural hair," she said. Her company has seen 42% annual growth since its founding, she said, adding: "We want to start a curl revolution."
Fashion Network
5 hours ago
- Fashion Network
'Curly is beautiful': Tunisian women embrace natural hair
In countries around the world, beauty standards have shifted radically in recent years, with a growing number of beauty salons and cosmetic brands in Tunisia promoting natural styles. Still, the battle is far from won, and many women in Tunisia still rush to get their hair straightened ahead of a wedding or a meeting, and some fear that if they do not wear their hair straight for a job interview, they might not get hired. Advocates for wearing one's natural hair believe that at the root of the stigma around curls lies a form of discrimination that they call "texturism". "The further you move away from what is considered Afro, kinky or curly, the more socially accepted you are," said Nawal Benali, a journalist and host of a podcast on racism in North Africa. "Because that's a marker of proper appearance and presentability." Benali said the standards had first been set in "the white, Western world", calling the obsession around straight hair an attempt to "erase our Indigenous and African features". Dhouha Mechergui, who co-founded Pineapple Studio, recalled having her hair straightened by her mother ahead of every religious holiday growing up. She said it took courage to make her own switch to natural, and that she had to work hard to convince women to embrace their curls and come to her salon. "Sometimes I play the role of psychiatrist, because I know making that decision is very difficult," she said. Aside from the drive for greater authenticity, health concerns have become a part of the debate, with one major study by the US National Institutes of Health linking chemical hair straightening products to a higher risk of uterine cancer. For generations, people around the world were told to straighten, braid, cut or otherwise conceal their curls, or else get sent home from school or work. A global drive buoyed by the Black Lives Matter movement gave rise to a major pandemic-era trend of beauty videos celebrating natural hair. The push did not go unnoticed: French lawmakers last year voted to ban discrimination based on hair texture, while several US states have passed similar legislation. Tunisia has no such initiative, so women entrepreneurs are leading the change. In 2021, Sirine Cherif cofounded Kamaana -- or "as I am" -- Tunisia's first homegrown haircare brand dedicated to curly locks. "When we started, we were the only specialised brand on the market," she said. "A few months later, there was a domino effect: bigger brands launched their own curly-hair lines." And today, Tunisian companies such as Zynia and Lilas Cosmetics have joined the growing industry. For Cherif, the boom is both a lucrative business opportunity and a marker of profound social change. "We are proud to have encouraged people to be themselves, to resist this societal pressure and embrace their natural hair," she said. Her company has seen 42% annual growth since its founding, she said, adding: "We want to start a curl revolution."
Euronews
15 hours ago
- Euronews
New malaria drug for newborns offers hope in Uganda
Alice Nekesa did not know she was infected with malaria-causing parasites until it was too late. She was in the fourth month of pregnancy last year when she started bleeding, a miscarriage later attributed to untreated malaria in her. The Ugandan farmer said recently that she regretted the loss of what would have been her second child 'because I didn't discover malaria and treat it early'. Variations of such cases are commonly reported by Ugandan health workers who witness stillbirths or feverish babies that die within days from undiagnosed malaria. The deaths are part of a wider death toll tied to the mosquito-borne disease, the deadliest across Africa, but one easily treated in adults who seek timely medical care. Until recently, a major gap in malaria treatment was how to care for newborns and infants infected with malaria who weren't strong enough to receive regular medication. That changed last month when Swiss medical regulators approved medicine from the Basel-based pharmaceutical company Novartis for babies weighing between 2 and 5 kilograms (about two to five kilograms). Swissmedic said the treatment, a sweet-tasting tablet that dissolves into a syrup when dropped into liquids like breast milk, was approved in coordination with the World Health Organization (WHO) under a fast-track authorisation process to help developing countries access much-needed treatment. Africa's 1.5 billion people accounted for 95 per cent of an estimated 597,000 malaria deaths worldwide in 2023, according to the WHO. More than three-quarters of those deaths were among children. In Uganda, an east African country of 45 million people, there were 12.6 million malaria cases and nearly 16,000 deaths in 2023. Many were children younger than five and pregnant women, the WHO said. Nigeria, Congo, and Uganda – in that order – are the African countries most burdened by malaria, a parasitic disease transmitted to humans through the bites of infected mosquitoes that thrive and breed in stagnant water. The drug approved by Swiss authorities, known as Coartem Baby in some countries and Riamet Baby in others, is a combination of two antimalarials. It is a lower dose version of a tablet previously approved for other age groups, including for older children. Before Coartem Baby, antimalarial drugs designed for older children were administered to small infants with careful adjustments to avoid overdose or toxicity. Ugandan authorities, who have been working to update clinical guidelines for treating malaria, say the new drug will be rolled out as soon as possible. It is not yet available in public hospitals. How the medicine could change malaria treatment The development of Coartem Baby has given hope to many, with local health workers and others saying the medicine will save the lives of many infants. Ronald Serufusa, the top malaria official for the district of Wakiso, which shares a border with the Ugandan capital of Kampala, said he believes Coartem Baby will be available 'very, very soon' and that one priority is sensitising the people adhering to treatment. Some private pharmacies already have access to Coartem Baby, 'flavored with orange or mango' to make it palatable for infants, he said. During the so-called malaria season, which coincides with rainy periods twice a year, long lines of sick patients grow outside government-run health centres across Uganda. Many are often women with babies strapped to their backs. Health workers now are trained to understand that 'malaria can be implicated among newborns,' even when other dangerous conditions like sepsis are present, Serufusa said. 'If they don't expand their investigations to also suspect malaria, then it goes unnoticed,' he said, speaking of health workers treating babies. The Malaria Consortium, a global nonprofit based in London, in a statement described the approval of Coartem Baby as 'a major leap forward for saving the lives of young children in countries affected by malaria'. In addition to Uganda, the drug will be rolled out in Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, and Tanzania, the group said. Jane Nabakooza, a pediatrician with Uganda's malaria control programme, said she expects the government will make Coartem Baby available to patients free of charge, even after losing funding when the United States shrank its foreign aid programme earlier this year. Some malaria funding from outside sources, including the Global Fund to Fight AIDS, Malaria and Tuberculosis, remains available for programmes such as indoor spraying to kill mosquitoes that spread the malaria-causing parasite. Because of funding shortages, 'we are focusing on those that are actually prone to severe forms of malaria and malaria deaths, and these are children under five years,' Nabakooza said.
